BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data

Reuters

Feb 17

Feb 17 (Reuters) - NRX Pharmaceuticals Inc NRXP.O:

NRX PHARMACEUTICALS $(NRXP)$ ANNOUNCES PATH TO NEW DRUG APPLICATION WITH REAL WORLD DATA AND BROADER PROPOSED INDICATION FOR NRX-100 (KETAMINE) FOLLOWING TYPE C FDA MEETING
NRX PHARMACEUTICALS INC - CO TO SEEK BROADER INDICATION FOR NRX-100 FOR DEPRESSION
NRX PHARMACEUTICALS: WILL USE CLINICAL TRIAL DATA IN HAND WITH PROPOSED REAL WORLD DATA FROM OSMIND TO APPLY FOR NRX-100 APPROVAL
NRX PHARMACEUTICALS INC - FDA ADVISES NO ADDITIONAL NONCLINICAL DATA NEEDED FOR NRX APPLICATION
NRX PHARMACEUTICALS INC - BELIEVES PATH FOR NRX-100 APPROVAL BASED ON EXISTING DATA

Source text: ID:nGNX6ZvC4Z

Further company coverage: NRXP.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612545430"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612545430\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612545430?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 20:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612545430","market":"fut","top_or_hot":-1,"title":"BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data </title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span>NRX Pharmaceuticals Inc <span>NRXP.O</span>:</p><ul><li><p>NRX PHARMACEUTICALS <a href=\"https://laohu8.com/S/NRXP\">$(NRXP)$</a> ANNOUNCES PATH TO NEW DRUG APPLICATION WITH REAL WORLD DATA AND BROADER PROPOSED INDICATION FOR NRX-100 (KETAMINE) FOLLOWING TYPE C FDA MEETING</p></li><li><p>NRX PHARMACEUTICALS INC - CO TO SEEK BROADER INDICATION FOR NRX-100 FOR DEPRESSION</p></li><li><p>NRX PHARMACEUTICALS: WILL USE CLINICAL TRIAL DATA IN HAND WITH PROPOSED REAL WORLD DATA FROM OSMIND TO APPLY FOR NRX-100 APPROVAL</p></li><li><p>NRX PHARMACEUTICALS INC - FDA ADVISES NO ADDITIONAL NONCLINICAL DATA NEEDED FOR NRX APPLICATION</p></li><li><p>NRX PHARMACEUTICALS INC - BELIEVES PATH FOR NRX-100 APPROVAL BASED ON EXISTING DATA</p></li></ul><p>Source text: <span>ID:nGNX6ZvC4Z</span></p><p>Further company coverage: <span>NRXP.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-17 20:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data </title></head><body><p><span>Feb 17 (Reuters)</span><span> - </span>NRX Pharmaceuticals Inc <span>NRXP.O</span>:</p><ul><li><p>NRX PHARMACEUTICALS <a href=\"https://laohu8.com/S/NRXP\">$(NRXP)$</a> ANNOUNCES PATH TO NEW DRUG APPLICATION WITH REAL WORLD DATA AND BROADER PROPOSED INDICATION FOR NRX-100 (KETAMINE) FOLLOWING TYPE C FDA MEETING</p></li><li><p>NRX PHARMACEUTICALS INC - CO TO SEEK BROADER INDICATION FOR NRX-100 FOR DEPRESSION</p></li><li><p>NRX PHARMACEUTICALS: WILL USE CLINICAL TRIAL DATA IN HAND WITH PROPOSED REAL WORLD DATA FROM OSMIND TO APPLY FOR NRX-100 APPROVAL</p></li><li><p>NRX PHARMACEUTICALS INC - FDA ADVISES NO ADDITIONAL NONCLINICAL DATA NEEDED FOR NRX APPLICATION</p></li><li><p>NRX PHARMACEUTICALS INC - BELIEVES PATH FOR NRX-100 APPROVAL BASED ON EXISTING DATA</p></li></ul><p>Source text: <span>ID:nGNX6ZvC4Z</span></p><p>Further company coverage: <span>NRXP.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRXP","symbol_name":"NRX Pharmaceuticals Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA21MT7C:1","article_id":"2612545430","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612545430","pubTimestamp":1771331280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data Feb 17 (Reuters) - NRX Pharmaceuticals Inc NRXP.O:NRX PHARMACEUTICALS (NASDAQ:NRXP) ANNOUNCES PATH TO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRXP":"NRX Pharmaceuticals Inc.","BK4007":"制药"},"translate_title":"简介-Nrx Pharmaceuticals（纳斯达克NRXP）宣布利用真实世界数据进行新药申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRXP":0.9},"content_text":"BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data Feb 17 (Reuters) - NRX Pharmaceuticals Inc NRXP.O:NRX PHARMACEUTICALS $(NRXP)$ ANNOUNCES PATH TO NEW DRUG APPLICATION WITH REAL WORLD DATA AND BROADER PROPOSED INDICATION FOR NRX-100 (KETAMINE) FOLLOWING TYPE C FDA MEETINGNRX PHARMACEUTICALS INC - CO TO SEEK BROADER INDICATION FOR NRX-100 FOR DEPRESSIONNRX PHARMACEUTICALS: WILL USE CLINICAL TRIAL DATA IN HAND WITH PROPOSED REAL WORLD DATA FROM OSMIND TO APPLY FOR NRX-100 APPROVALNRX PHARMACEUTICALS INC - FDA ADVISES NO ADDITIONAL NONCLINICAL DATA NEEDED FOR NRX APPLICATIONNRX PHARMACEUTICALS INC - BELIEVES PATH FOR NRX-100 APPROVAL BASED ON EXISTING DATASource text: ID:nGNX6ZvC4ZFurther company coverage: NRXP.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}